A Phase 1 Study to Demonstrate the Relative Bioavailability of Fixed Dose Combinations of Ambrisentan and Tadalafil in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 11 Aug 2017
At a glance
- Drugs Ambrisentan/tadalafil (Primary) ; Ambrisentan; Tadalafil
- Indications Pulmonary hypertension
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 08 Aug 2017 Status changed from recruiting to completed.
- 04 Apr 2017 Planned number of patients changed from 60 to 106.
- 04 Apr 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Aug 2017.